Clinical trials: Diabetic Peripheral Neuropathic Pain (DPN)
- Condition Diabetic Peripheral Neuropathic Pain (DPN)
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Neuropathic Pain, Diabetic Peripheral Neuropathy (DPN)
Oral LAT8881 in Neuropathic Pain
This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.
- Conditions
- Neuropathic Pain, Diabetic Peripheral Neuropathy (DPN), Post Herpetic Neuralgia (PHN)
- Trial name
- NCT03865953
- Testing
- LAT8881
- Where
- 6 sites in Australia, United Kingdom
- Volunteers
- 53 people
- Sponsor
- Lateral Pharma Pty Ltd
Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN)
Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Management of neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency virus-related peripheral neuropathy, and chemotherapy induced peripheral neuropathy.
- Conditions
- Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN), HIV-related Neuropathic Pain (HIV), Chemotherapy Induced Neuropathic Pain
- Trial name
- NCT00407511
- Testing
- Pregabalin
- Where
- 11 sites in Colombia, Ecuador and 3 more
- Volunteers
- 121 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.